ATE368054T1 - Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität - Google Patents

Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität

Info

Publication number
ATE368054T1
ATE368054T1 AT98963311T AT98963311T ATE368054T1 AT E368054 T1 ATE368054 T1 AT E368054T1 AT 98963311 T AT98963311 T AT 98963311T AT 98963311 T AT98963311 T AT 98963311T AT E368054 T1 ATE368054 T1 AT E368054T1
Authority
AT
Austria
Prior art keywords
modulating agents
occludin
cell adhesion
methods
compounds
Prior art date
Application number
AT98963311T
Other languages
English (en)
Inventor
Orest W Blaschuk
Barbara Gour
James Matthew Symonds
Original Assignee
Adherex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adherex Technologies Inc filed Critical Adherex Technologies Inc
Application granted granted Critical
Publication of ATE368054T1 publication Critical patent/ATE368054T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT98963311T 1997-12-31 1998-12-30 Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität ATE368054T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/001,511 US6248864B1 (en) 1997-12-31 1997-12-31 Compounds and methods and modulating tissue permeability

Publications (1)

Publication Number Publication Date
ATE368054T1 true ATE368054T1 (de) 2007-08-15

Family

ID=21696412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963311T ATE368054T1 (de) 1997-12-31 1998-12-30 Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität

Country Status (9)

Country Link
US (3) US6248864B1 (de)
EP (1) EP1042365B1 (de)
JP (1) JP2002509073A (de)
AT (1) ATE368054T1 (de)
AU (1) AU764790B2 (de)
CA (1) CA2351624A1 (de)
DE (1) DE69838147T2 (de)
ES (1) ES2292211T3 (de)
WO (1) WO1999035166A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797807B1 (en) * 1997-12-31 2004-09-28 Adherex Technologies, Inc. Compounds and methods for cancer therapy
AU746454B2 (en) * 1998-03-02 2002-05-02 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
PT1207905E (pt) * 1999-09-03 2010-12-07 Brigham & Womens Hospital Métodos e composições para o tratamento de doença inflamatória utilizando agentes moduladores da caderina-11
US7164001B2 (en) * 2000-01-20 2007-01-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001053480A1 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
US20020077775A1 (en) * 2000-05-25 2002-06-20 Schork Nicholas J. Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
US20030195707A1 (en) * 2000-05-25 2003-10-16 Schork Nicholas J Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
CA2415690A1 (en) * 2000-07-14 2002-01-24 Chiron Corporation Tetraspan protein and uses thereof
WO2002034880A2 (en) * 2000-10-23 2002-05-02 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
US20020192206A1 (en) * 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
JP2005511012A (ja) * 2001-08-10 2005-04-28 セローノ ジェネティクス インスティテュート ソシエテ アノニム ヒトｃＤＮＡおよびタンパク質およびその使用
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003102538A2 (en) * 2002-05-30 2003-12-11 European Molecular Biology Laboratory Combinatorial chemical library ii
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
EP1384469A1 (de) * 2002-07-25 2004-01-28 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Tight Junctions
EP1384468A1 (de) * 2002-07-25 2004-01-28 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Tight Junctions
AU2003298475A1 (en) * 2002-11-14 2004-06-18 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
US7456153B2 (en) * 2002-11-14 2008-11-25 Adherex Technologies Inc. Compounds and methods for modulating functions of classical cadherins
CA2523870A1 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
WO2006071878A1 (en) * 2004-12-28 2006-07-06 Emory Unversity Methods and compositions for treating epithelial cancers
NZ562234A (en) * 2005-04-26 2009-09-25 Pfizer P-cadherin antibodies
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
CN104803957A (zh) 2007-04-02 2015-07-29 泰拉科斯有限公司 苄基化糖苷衍生物及其用法
WO2009026537A1 (en) 2007-08-23 2009-02-26 Theracos, Inc. Benzylbenzene derivatives and methods of use
WO2009102367A2 (en) * 2007-11-19 2009-08-20 The Regents Of The University Of Colorado Tight junction protein modulators and uses thereof
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
PT2324002T (pt) 2008-08-22 2016-11-09 Theracos Sub Llc Processos para a preparação de inibidores de sglt2
EP2344534A4 (de) * 2008-10-03 2012-03-28 Univ Rockefeller Neuer hcv-eintrittsfaktor, occludin
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
EP2445506B1 (de) 2009-06-24 2014-12-31 Entarco SA Die verwendung von spinosyn und spinosyn enthaltenden zubereitungen zur behandlung von protozoen verursachten erkrankungen, von viralen infektionen und von krebs.
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
CA2800176C (en) 2010-05-24 2018-08-28 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2654757A1 (de) 2010-12-22 2013-10-30 Entarco SA Verwendung von spinosynen und spinosynzusammensetzungen als lokalanästhetika und antiarrhythmika
US9592288B2 (en) 2011-02-18 2017-03-14 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
US10214561B2 (en) 2014-02-07 2019-02-26 Miyarisan Pharmaceutical Co., Ltd. Peptide having activity of inhibiting production of toxin by bacterium belonging to genus clostridium
JP6566444B2 (ja) 2014-03-19 2019-08-28 カーザ グローバル エルエルシーＣｕｒｚａ Ｇｌｏｂａｌ， Ｌｌｃ ２−（アシルアミノ）イミダゾールを含む組成物および方法
WO2016100301A1 (en) 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
CN108084257B (zh) * 2016-11-23 2020-06-12 深圳市安群生物工程有限公司 人闭锁蛋白抗原表位肽、抗原、抗体、试剂盒及应用
JP2020512981A (ja) 2017-03-31 2020-04-30 カーザ グローバル，リミティド ライアビリティ カンパニー 置換２−アミノイミダゾールを含む組成物と方法
BR112021003156A2 (pt) 2018-08-23 2021-05-11 Seagen, Inc. composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
WO2022217026A1 (en) 2021-04-09 2022-10-13 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2024225703A1 (ko) * 2023-04-26 2024-10-31 서울대학교산학협력단 C-n 결합으로 환형화된 새로운 환형 펩타이드계열 화합물, 이의 생산 방법 및 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1464704B1 (de) 1996-03-07 2006-10-11 Eisai Co., Ltd. Mäuse Adhesions Molekül Occludin
US6252045B1 (en) 1996-03-15 2001-06-26 Yale University Human occludin, its uses and enhancement of drug absorption using occludin inhibitors
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity

Also Published As

Publication number Publication date
DE69838147T2 (de) 2008-05-29
US6310177B1 (en) 2001-10-30
US6248864B1 (en) 2001-06-19
WO1999035166A1 (en) 1999-07-15
EP1042365B1 (de) 2007-07-25
US6110747A (en) 2000-08-29
ES2292211T3 (es) 2008-03-01
CA2351624A1 (en) 1999-07-15
AU1866599A (en) 1999-07-26
JP2002509073A (ja) 2002-03-26
AU764790B2 (en) 2003-08-28
EP1042365A1 (de) 2000-10-11
DE69838147D1 (de) 2007-09-06

Similar Documents

Publication Publication Date Title
DE69838147D1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE69832293D1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
ATE369878T1 (de) Träger-pharmaka-konjugate
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
ATE218579T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE60006100D1 (de) Lang wirkende insulinotrope peptide
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60032486D1 (de) Prion protein peptide und deren verwendung
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
EP1401467A4 (de) Alpha-fetoprotein-peptide und ihre verwendung
MXPA04000317A (es) Un copolimero de bloque amfifilico cargado positivamente como un vehiculo de medicamento y complejo del mismo con un medicamento cargado negativamente.
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties